ATF3 and gastric cancer: Our data suggest that ATF3 acts as a brake in the Wnt/β-catenin signaling axis in normal gastric epithelial cells, which provides a targeting strategy using ATF3 and its regulatory factors as potential biomarkers and therapeutic targets for GC patients.